We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Calman A. MacLennan

Contact information

Email
calman.maclennan@ndm.ox.ac.uk

PA
Raquel Gomez-Menor Munoz
raquel.gomez-menor@ndm.ox.ac.uk

Website
https://www.jenner.ac.uk/

Colleges

Green Templeton College

Calman A. MacLennan

BM, BCh, DPhil, FHEA, FRCP, FRCPath

Professor of Vaccine Immunology (University of Birmingham)

Jenner Investigator and Group Leader - Gonococcal Vaccine Project, Jenner Institute
Director of BactiVac, the Bacterial Vaccines Network, Institute of Immunology and Immunotherapy, University of Birmingham, UK
Consultant Immunologist, Oxford University Hospitals NHS Foundation Trust, UK
Senior Program Officer, Bacterial Vaccines, Global Health, Enteric & Diarrheal Diseases, Bill & Melinda Gates Foundation, Seattle, US

Vaccinologist, Immunologist & Clinician Scientist focused on bacterial infections and AMR

Calman MacLennan is a clinician scientist, vaccinologist and immunologist who joined the Jenner Institute in 2015. For the past 25 years, his career has focused on understanding mechanisms of immunological of protection against bacterial infections of global health significance and antimicrobial resistance (AMR) concern. This knowledge has then been applied to the development of protective vaccines.

With experience of vaccine development in academia and industry, he has been involved in the development of several bacterial vaccines including one licensed vaccine against typhoid and other vaccines currently in clinical trials.

He leads the Gonococcal Vaccine Project which is using native Outer Membrane Vesicle (nOMV) technology to develop a candidate vaccine against Neisseria gonorrhoeae, the causative agent of gonorrhoea. Gonorrhoea infects 82.4 million people each year and is rapidly becoming resistant to all known antibiotics.

Professor MacLennan is the founder and director of BactiVac, the Bacterial Vaccines Network, a worldwide network based out of the University of Birmingham with a mission to accelerate the development of vaccines against bacterial pathogens as a countermeasure to AMR. He is a Consultant Immunologist at the Oxford University Hospitals NHS Foundation Trust.

Key publications

Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data

Cohen D. et al, (2023), Clinical Microbiology and Infection, 29, 366 - 371

Impact and Control of Sugar Size in Glycoconjugate Vaccines

Stefanetti G. et al, (2022), Molecules, 27

The Shigella Vaccines Pipeline

MacLennan CA. et al, (2022), Vaccines, 10

Critical Needs in Advancing Shigella Vaccines for Global Health

Maclennan CA. et al, (2022), Journal of Infectious Diseases, 225, 1500 - 1503

Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine

Micoli F. et al, (2020), Proceedings of the National Academy of Sciences of the United States of America, 117, 24443 - 24449

Outer membrane vesicle vaccines

Micoli F. and MacLennan CA., (2020), Seminars in Immunology, 50

Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella

Micoli F. et al, (2018), Proceedings of the National Academy of Sciences of the United States of America, 115, 10428 - 10433

Presentation of life-threatening invasive nontyphoidal Salmonella disease in Malawian children: A prospective observational study

MacLennan CA. et al, (2017), Plos Neglected Tropical Diseases, 11

Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1

Marini A. et al, (2017), Plos One, 12

Cytokine profiles in Malawian children presenting with uncomplicated malaria, severe malarial anemia, and cerebral malaria

Mandala WL. et al, (2017), Clinical and Vaccine Immunology, 24

Characterization of O-antigen delivered by Generalized Modules for Membrane Antigens (GMMA) vaccine candidates against nontyphoidal Salmonella

De Benedetto G. et al, (2017), Vaccine, 35, 419 - 426

A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014)

Uche IV. et al, (2017), Plos Neglected Tropical Diseases, 11

Brief Report: Immunization of HIV-Infected Adults in the UK with Haemophilus influenzae b/Meningococcal C Glycoconjugate and Pneumococcal Polysaccharide Vaccines

MacLennan CA. et al, (2016), Journal of Acquired Immune Deficiency Syndromes, 73, 287 - 293

Cytokine profiles during invasive nontyphoidal salmonella disease predict outcome in african children

Gilchrist JJ. et al, (2016), Clinical and Vaccine Immunology, 23, 601 - 609

Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection

Goh YS. et al, (2016), PLoS Neglected Tropical Diseases, 10

Genetic susceptibility to invasive Salmonella disease

Gilchrist JJ. et al, (2015), Nature Reviews Immunology, 15, 452 - 463

Monoclonal antibodies of a diverse isotype induced by an O-antigen glycoconjugate vaccine mediate in vitro and in vivo killing of African invasive nontyphoidal Salmonella

Goh YS. et al, (2015), Infection and Immunity, 83, 3722 - 3731

Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium

Rondini S. et al, (2015), Infection and Immunity, 83, 996 - 1007

Vaccines against poverty

MacLennan CA. and Saul A., (2014), Proceedings of the National Academy of Sciences of the United States of America, 111, 12307 - 12312

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)

Koeberling O. et al, (2014), Vaccine, 32, 2688 - 2695

Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X

Micoli F. et al, (2013), Proceedings of the National Academy of Sciences of the United States of America, 110, 19077 - 19082

Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-Infected african adults

MacLennan CA. et al, (2010), Science, 328, 508 - 512

Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans

Gondwe EN. et al, (2010), Proceedings of the National Academy of Sciences of the United States of America, 107, 3070 - 3075

The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children

MacLennan CA. et al, (2008), Journal of Clinical Investigation, 118, 1553 - 1562

More publications